US Patent 8,454,996: Scope, Claims, Expiration, and Buprenorphine Patent Landscape

US Patent 8,454,996 protects a particle-engineered sublingual buprenorphine formulation and methods of administering it. The patent is directed to buprenorphine microparticles attached to the exterior surfaces of substantially larger, water-soluble carrier particles, combined with a saliva-activated bioadhesive or mucoadhesive polymer. Its principal commercial relevance is to rapidly dissolving sublingual buprenorphine products, including formulations competing with Suboxone and Zubsolv.

The patent does not broadly cover every sublingual buprenorphine tablet. Infringement requires the accused product and administration method to satisfy the claimed particle architecture, carrier composition, adhesive-agent limitations, and sublingual-use requirements.

What does US Patent 8,454,996 cover?

US 8,454,996 covers methods of administering an essentially water-free sublingual buprenorphine composition in which drug microparticles are presented on larger, water-soluble carrier particles.

Core technical architecture

Claim element	Required characteristic
Active ingredient	Buprenorphine or a pharmaceutically acceptable salt
Drug form	Microparticles
Carrier	Water-soluble particles substantially larger than the drug microparticles
Drug location	Microparticles adhered to or presented at the carrier-particle exterior surfaces
Adhesive component	Bioadhesion- or mucoadhesion-promoting agent
Adhesive chemistry	Polymer that swells on contact with saliva for claim 1
Dosage form	Tablet sized for placement under the tongue for claim 1
Administration route	Sublingual administration
Water content	Essentially water-free composition in claim 2

The specification’s central distinction is the distribution of small buprenorphine particles on the surfaces of larger soluble carrier particles. That arrangement is intended to improve drug exposure to saliva, accelerate dissolution, and promote retention under the tongue.

The claims are method claims. They require an act of sublingual administration to an individual, not merely manufacture or sale of a composition.

What are the independent claims of US 8,454,996?

Claim 1: Sublingual tablet with surface-presented drug microparticles

Claim 1 requires:

Sublingual administration to an individual.
A pharmaceutical composition in tablet form.
A tablet sized for placement under the tongue.
Water-soluble carrier particles having exterior surfaces.
Buprenorphine microparticles or a pharmaceutically acceptable salt.
Drug microparticles smaller than the carrier particles.
Drug microparticles admixed with the carrier particles.
A bioadhesion or mucoadhesion-promoting agent.
The adhesive agent must consist essentially of a saliva-swelling polymer.
The adhesive particles must be admixed with the carrier particles.
The buprenorphine microparticles must be presented at the exterior surfaces of the carrier particles.

The phrase “consisting essentially of” narrows the adhesive-agent limitation. It generally permits components that do not materially alter the claimed adhesive function, but it creates a stronger argument against formulations using materially different adhesive mechanisms or polymer systems.

Claim 2: Essentially water-free dosage unit

Claim 2 is broader in some respects because it does not expressly require a tablet sized for placement under the tongue or specify that the polymer swells on contact with saliva. It requires:

Sublingual administration of at least one dosage unit.
An essentially water-free composition.
An effective amount of buprenorphine or its pharmaceutically acceptable salt.
Buprenorphine microparticles adhered to carrier-particle surfaces.
Carrier particles substantially larger than the microparticles.
Essentially water-soluble carrier particles.
A bioadhesion or mucoadhesion-promoting agent.

Claim 2 therefore concentrates on the formulation’s physical architecture and administration route. It may reach products that do not use the exact tablet and polymer limitations recited in claim 1.

How does the particle architecture limit infringement?

The patent’s strongest limitation is the required spatial relationship between the drug and carrier particles.

A potentially infringing formulation must have:

Drug in microparticle form.
Carrier particles larger than the drug microparticles.
Drug microparticles located on, adhered to, or presented at the carrier exterior.
A water-soluble carrier.
A bioadhesive or mucoadhesive component.
Sublingual administration.

A conventional tablet containing uniformly blended buprenorphine powder, without the claimed surface presentation, is less likely to fall within the independent claims. The same applies to a tablet in which buprenorphine is molecularly dispersed in a polymer matrix, compressed as a conventional granulation, or incorporated into a film without the claimed carrier-particle arrangement.

Surface presentation is a material limitation

“Presented at the exterior surfaces” is more specific than merely being mixed with carrier particles. The claim focuses on drug availability at the particle interface. A technical infringement analysis would likely examine:

Scanning electron microscopy.
Particle-size distributions.
Elemental or chemical mapping.
Cross-sectional imaging.
Dissolution and wetting behavior.
Manufacturing records describing coating, adhesion, deposition, or surface loading.
Excipient identity and concentration.

A formulation may avoid the claims if the buprenorphine is embedded within the carrier particles rather than located on their exterior surfaces. The distinction will depend on claim construction and the factual evidence concerning particle morphology.

What formulations are protected by US 8,454,996?

The patent can cover sublingual formulations using different buprenorphine salts, provided the formulation satisfies the other limitations.

Potentially covered formulation categories

Formulation characteristic	Relevance
Buprenorphine base microparticles	Potentially covered
Buprenorphine hydrochloride microparticles	Potentially covered
Surface-loaded soluble sugar particles	Potentially covered
Surface-loaded soluble polyol particles	Potentially covered
Saliva-swelling polymer	Particularly relevant to claim 1
Tablet dosage unit	Required by claim 1
Film or non-tablet dosage unit	Potentially relevant to claim 2 if other limitations are met
Conventional homogeneous blend	May avoid the surface-presentation limitation
Molecularly dispersed drug matrix	May avoid the microparticle/carrier architecture
Injectable or transdermal product	Outside the sublingual-use requirement

The claims do not expressly require naloxone. A buprenorphine-only product and a buprenorphine/naloxone product could both implicate the claims if their formulations satisfy the claimed structure.

The claims also do not specify a particular buprenorphine dose, buprenorphine-to-naloxone ratio, flavor system, tablet weight, dissolution time, or commercial brand.

When does US Patent 8,454,996 expire?

Event	Date or status
US patent number	8,454,996
Issue date	June 4, 2013
Earliest priority date	June 6, 2007
Expected base patent expiration	June 6, 2027
Patent term adjustment	Must be included if reflected in the USPTO patent record
Patent term extension	No FDA patent-term extension is identified for the formulation patent
Post-expiration risk	Regulatory exclusivity, separate patents, trade secrets, and product-specific patents may remain relevant

The expected term is calculated from the earliest claimed priority structure and the applicable 20-year patent term rules. The issue date does not control the expiration date. A generic or follow-on applicant must assess the patent’s current USPTO term, any patent-term adjustment, terminal disclaimer, reexamination certificate, and Orange Book listing.

What is the Orange Book status of US 8,454,996?

US 8,454,996 has been associated with the patent estate for Orexo’s Zubsolv buprenorphine/naloxone sublingual tablet. Zubsolv is an FDA-approved sublingual tablet containing buprenorphine hydrochloride and naloxone hydrochloride.

FDA product context

Product	Sponsor	Dosage form	Active ingredients	FDA pathway
Zubsolv	Orexo US, Inc.	Sublingual tablet	Buprenorphine/naloxone	NDA
Suboxone sublingual tablet	Indivior or predecessor sponsors	Sublingual tablet	Buprenorphine/naloxone	NDA
Suboxone sublingual film	Indivior	Sublingual film	Buprenorphine/naloxone	NDA
Bunavail	BioDelivery Sciences, later collegiate commercial ownership	Buccal film	Buprenorphine/naloxone	NDA

The Orange Book inquiry should distinguish three issues:

Whether US 8,454,996 is currently listed against a specific NDA.
Whether the listing covers the approved product as a formulation or method patent.
Whether the patent remains relevant to an ANDA applicant after considering its expiration date and any later-listed patents.

A patent can be technically relevant to a product without creating a current Orange Book certification obligation if it is not listed for the relevant NDA or has expired.

Which companies are challenging the Zubsolv patent estate?

The principal commercial challengers in the buprenorphine/naloxone market have included generic manufacturers pursuing ANDAs for sublingual tablets or films. The most relevant potential challengers are companies such as Teva, Actavis or Allergan, Mylan or Viatris, Sandoz, and Dr. Reddy’s Laboratories, depending on the product and filing period.

A Paragraph IV challenge to US 8,454,996 would typically assert one or more of the following:

The claims are anticipated by an earlier particle-based sublingual formulation.
The claimed particle arrangement would have been obvious.
The specification does not adequately describe or enable the full claim scope.
The claims are indefinite, particularly terms such as “presented,” “essentially water-free,” “substantially larger,” or “effective amount.”
The accused ANDA product does not contain drug microparticles at carrier-particle exterior surfaces.
The ANDA product does not use the claimed bioadhesive or mucoadhesive agent.
The patent is expired or unenforceable.

A Paragraph IV notice does not establish invalidity or noninfringement. The patentee must sue within the statutory period to obtain the automatic 30-month stay of ANDA approval under the Hatch-Waxman framework. The relevant case record should be reviewed in PACER and the FDA Orange Book rather than inferred solely from the existence of an ANDA.

How strong is the patent estate for US 8,454,996?

The patent is technically focused and potentially valuable against products that copy the same particle-engineering concept. Its strength varies by claim and enforcement theory.

Strengths

The claims identify a specific drug-delivery architecture.
The surface presentation of buprenorphine creates a measurable structural limitation.
The patent can reach buprenorphine-only and buprenorphine/naloxone products.
Claim 2 does not require the full tablet and saliva-swelling-polymer language of claim 1.
A product’s commercial label may establish sublingual administration.

Vulnerabilities

Method claims require proof of administration, not merely manufacture.
“Essentially water-free” may create claim-construction and evidentiary disputes.
“Presented at the exterior surfaces” may be difficult to prove without confidential formulation data.
Prior art involving carrier particles, surface loading, mucoadhesion, and sublingual buprenorphine may support obviousness arguments.
The patent’s remaining term is limited, with expected expiration in 2027.
Separate patents may provide a stronger barrier for product-specific composition, dosage, or manufacturing features.

The claim set is stronger against a formulation that expressly uses surface-deposited buprenorphine microparticles on soluble carrier particles than against a formulation using a different drug-dispersion technology.

How does US 8,454,996 compare with competing buprenorphine patents?

Patent category	Typical protected subject matter	Relevance to 8,454,996
Buprenorphine composition patents	Drug, salt, ratio, dosage, or excipient combinations	May create independent barriers
Particle-engineering patents	Microparticles, carrier particles, surface loading	Closest technical overlap
Mucoadhesive patents	Polymers and retention systems	May overlap with claim 1
Film patents	Buccal or sublingual polymer films	Usually distinct from tablet claims
Method-of-use patents	Opioid-dependence treatment, dosing, induction, maintenance	Separate method-of-treatment risk
Manufacturing patents	Granulation, coating, particle deposition, compression	Important for supply-chain control
Orange Book product patents	Patents listed against an approved NDA	Direct ANDA litigation significance

The estate should be analyzed as a portfolio, not as a single patent. A generic applicant that designs around the carrier-particle architecture may still face separate patents covering the approved dosage form, manufacturing process, tablet composition, or method of use.

What generic launch scenarios exist?

Launch after patent expiration

The lowest litigation risk generally occurs after all relevant Orange Book patents expire and FDA exclusivity has ended. A generic applicant may then launch if it satisfies FDA approval requirements and no separate enforceable patent remains.

Paragraph III certification

An ANDA applicant may certify that it will not market until US 8,454,996 expires. This approach avoids an immediate validity dispute but delays approval or launch until the patent term ends.

Paragraph IV certification

An applicant may challenge the patent by asserting invalidity, unenforceability, or noninfringement. Litigation risk is highest where the generic reproduces the claimed surface-loaded particle technology.

Design-around launch

A technically differentiated product could use:

Drug embedded inside carrier particles.
A molecular dispersion rather than drug microparticles.
A non-water-soluble carrier.
A different delivery matrix.
A film or dosage form that avoids the claimed architecture.
A formulation without the claimed bioadhesive system.

A design-around must be evaluated against every claim limitation and the full related patent family.

What manufacturing and intellectual-property barriers matter?

The patent may impose a manufacturing barrier because the claimed product requires control over particle size, surface loading, adhesion, and excipient distribution. Relevant process steps may include:

Micronization of buprenorphine.
Deposition or adhesion of microparticles onto soluble carriers.
Blending with bioadhesive polymer particles.
Water exclusion during processing and storage.
Compression into a low-mass sublingual tablet.
Uniformity testing at low drug loads.

Manufacturing know-how may remain commercially important after patent expiry if the process is difficult to reproduce or supported by trade secrets. However, trade secrets do not prevent independent development using publicly available formulation information.

What litigation and settlement issues should be reviewed?

For a complete freedom-to-operate assessment, the relevant record includes:

US 8,454,996 and its prosecution history.
The full patent family and continuation applications.
FDA Orange Book listings for Zubsolv and related products.
ANDA Paragraph IV notices.
District-court complaints and claim-construction orders.
Federal Circuit decisions.
Settlement agreements and any authorized-generic provisions.
Product-specific patents listed after the original approval.
Terminal disclaimers and patent-term-adjustment records.

Settlements can materially change launch timing even when a patent remains facially valid. A settlement may permit an authorized generic, a delayed generic entry date, or entry before patent expiration under specified conditions.

Key Takeaways

US 8,454,996 targets a defined sublingual buprenorphine particle architecture.
The key limitation is buprenorphine microparticles presented on the exterior surfaces of larger, water-soluble carrier particles.
Claim 1 adds a tablet limitation and a saliva-swelling polymer limitation.
Claim 2 is broader in dosage-form language but requires an essentially water-free composition and the same general particle architecture.
The patent does not cover every buprenorphine tablet or film.
Buprenorphine/naloxone products may implicate the claims even though naloxone is not recited.
The expected base expiration date is June 6, 2027.
Orange Book relevance depends on the patent’s listing against the specific NDA and the current FDA record.
The principal generic strategies are Paragraph III certification, Paragraph IV litigation, and technical design-around.
Separate formulation, method-of-use, manufacturing, and product patents may create additional launch barriers.

FAQs About US Patent 8,454,996 and Buprenorphine Exclusivity

Does US 8,454,996 cover Suboxone film?

Not automatically. Suboxone film would fall within the patent only if its formulation and use satisfy the claimed carrier-particle and surface-presented microparticle limitations. A film-specific formulation may avoid the tablet limitation in claim 1, but claim 2 must still be assessed.

Does the patent require naloxone?

No. The claims recite buprenorphine or a pharmaceutically acceptable salt. Naloxone is not required.

Can a generic avoid the patent by using larger buprenorphine particles?

Possibly, if the particles no longer qualify as microparticles or are not smaller than substantially larger carrier particles. The result depends on the intrinsic evidence, technical definitions, and claim construction.

Does patent expiration automatically permit a generic launch?

No. Launch also depends on FDA approval, other unexpired patents, regulatory exclusivity, injunctions, settlement restrictions, and any separate patents covering the product or manufacturing process.

Is US 8,454,996 a method-of-use patent or a formulation patent?

It is formally a method patent because the claims require sublingual administration. Its substantive limitations are formulation-based, so infringement analysis will focus heavily on the composition’s particle structure and excipient system.

References

U.S. Patent No. 8,454,996. (2013). Pharmaceutical composition. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Zubsolv (buprenorphine and naloxone) sublingual tablets: Prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Suboxone (buprenorphine and naloxone) sublingual film: Prescribing information. FDA.
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355.
Patent Term Adjustment Act, 35 U.S.C. § 154.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	9803240	Sep 24, 1998

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2236132	⤷ Start Trial	C300714	Netherlands	⤷ Start Trial
European Patent Office	2236132	⤷ Start Trial	CA 2015 00004	Denmark	⤷ Start Trial
European Patent Office	2236132	⤷ Start Trial	92636	Luxembourg	⤷ Start Trial
European Patent Office	2236132	⤷ Start Trial	122015000006	Germany	⤷ Start Trial
European Patent Office	2236132	⤷ Start Trial	484	Finland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,454,996

Summary for Patent: 8,454,996